RxDoctor Payments Data

Rocio Neri-Hernandez, NP

Nurse Practitioner · San Antonio, TXNPI 1285095307

Payments from drug & device makers

$1,680in general payments, 2019–2025

Across 35 payments — averaging $48.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$600
  • Smith+Nephew$581
  • Solventum Corporation$114
  • Organogenesis Inc.$103
  • Kerecis Limited$100
  • Urgo Medical North America, LLC$72
  • plus $110 from 4 others

What the payments were for

  • Food & beverage$1,680100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,680 in reported general payments places this provider in the 80th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$3,914
Medicare patients
32
Services billed
83

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciclopirox554$22,256
SantylCollagenase Clostridium Hist.13$8,706
Doxycycline Monohydrate106$2,692
Fluconazole53$2,382
Doxycycline Hyclate135$2,337
Linezolid19$1,880
Terbinafine Hcl67$1,781
SsdSilver Sulfadiazine93$1,249
Ciprofloxacin Hcl83$1,233
Clindamycin Hcl70$1,019
Clindamycin Phosphate13$663
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav29$657
Triamcinolone Acetonide39$630
Levofloxacin100$623
Mupirocin56$591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$581$8,70613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →